BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Grellier L, Mutimer D, Ahmed M, Brown D, Burroughs AK, Rolles K, McMaster P, Beranek P, Kennedy F, Kibbler H, McPhillips P, Elias E, Dusheiko G. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet. 1996;348:1212-1215. [PMID: 8898039 DOI: 10.1016/s0140-6736(96)04444-3] [Cited by in Crossref: 299] [Cited by in F6Publishing: 47] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Sokal E. Drug treatment of pediatric chronic hepatitis B. Paediatr Drugs. 2002;4:361-369. [PMID: 12038872 DOI: 10.2165/00128072-200204060-00003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
2 Ishigami M, Ogura Y, Hirooka Y, Goto H. Change of strategies and future perspectives against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2015; 21(36): 10290-10298 [PMID: 26420956 DOI: 10.3748/wjg.v21.i36.10290] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
3 Shen S, Jiang L, Xiao GQ, Yan LN, Yang JY, Wen TF, Li B, Wang WT, Xu MQ, Wei YG. Prophylaxis against hepatitis B virus recurrence after liver transplantation: A registry study. World J Gastroenterol 2015; 21(2): 584-592 [PMID: 25593480 DOI: 10.3748/wjg.v21.i2.584] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
4 Delaney WE 4th, Miller TG, Isom HC. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob Agents Chemother 1999;43:2017-26. [PMID: 10428929 DOI: 10.1128/AAC.43.8.2017] [Cited by in Crossref: 52] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
5 Castells L. [Viral hepatitides infections in transplant recipients]. Enferm Infecc Microbiol Clin 2006;24:118-28. [PMID: 16545319 DOI: 10.1157/13085018] [Reference Citation Analysis]
6 Gordon FH, Mistry PK, Sabin CA, Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut. 1998;42:744-749. [PMID: 9659174 DOI: 10.1136/gut.42.5.744] [Cited by in Crossref: 104] [Cited by in F6Publishing: 80] [Article Influence: 4.3] [Reference Citation Analysis]
7 Yurdaydin C, Idilman R. Therapy of Delta Hepatitis. Cold Spring Harb Perspect Med 2015;5:a021543. [PMID: 26253093 DOI: 10.1101/cshperspect.a021543] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
8 Tsai MC, Chen YT, Chien YS, Chen TC, Hu TH. Hepatitis B virus infection and renal transplantation. World J Gastroenterol 2010; 16(31): 3878-3887 [PMID: 20712048 DOI: 10.3748/wjg.v16.i31.3878] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
9 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2006; 14(10): 939-941 [DOI: 10.11569/wcjd.v14.i10.939] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
10 Walters KA, Tipples GA, Allen MI, Condreay LD, Addison WR, Tyrrell L. Generation of stable cell lines expressing Lamivudine-resistant hepatitis B virus for antiviral-compound screening. Antimicrob Agents Chemother 2003;47:1936-42. [PMID: 12760870 DOI: 10.1128/AAC.47.6.1936-1942.2003] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Kreutz C. Molecular, immunological and clinical properties of mutated hepatitis B viruses. J Cell Mol Med. 2002;6:113-143. [PMID: 12003675 DOI: 10.1111/j.1582-4934.2002.tb00317.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 2.4] [Reference Citation Analysis]
12 McCaughan GW. Prevention of post liver transplant HBV recurrence. Hepatol Int. 2011; Aug 10. [Epub ahead of print]. [PMID: 22020819 DOI: 10.1007/s12072-011-9293-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
13 Fung J. Management of chronic hepatitis B before and after liver transplantation. World J Hepatol 2015; 7(10): 1421-1426 [PMID: 26052387 DOI: 10.4254/wjh.v7.i10.1421] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
14 Roche B, Roque-Afonso AM, Nevens F, Samuel D. Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin. Transplantation. 2015;99:1321-1334. [PMID: 26038873 DOI: 10.1097/tp.0000000000000777] [Cited by in Crossref: 41] [Cited by in F6Publishing: 13] [Article Influence: 6.8] [Reference Citation Analysis]
15 Partovi N, Guy M, Ensom M, Noble M, Yoshida E. A Study of the Pharmacokinetic Profile of Low-Dose Hepatitis B Immune Globulin in Long-Term Liver Transplant Recipients for Chronic Hepatitis B Infection: Pharmacokinetic Profile of Low-Dose HBIG. American Journal of Transplantation 2001;1:51-4. [DOI: 10.1034/j.1600-6143.2001.010110.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
16 Lo CM, Cheung ST, Lai CL, Liu CL, Ng IO, Yuen MF, Fan ST, Wong J. Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis. Ann Surg 2001;233:276-81. [PMID: 11176135 DOI: 10.1097/00000658-200102000-00018] [Cited by in Crossref: 107] [Cited by in F6Publishing: 92] [Article Influence: 5.1] [Reference Citation Analysis]
17 Schreibman IR, Schiff ER. Prevention and treatment of recurrent Hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann Clin Microbiol Antimicrob 2006;5:8. [PMID: 16600049 DOI: 10.1186/1476-0711-5-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
18 Fan ST. Liver transplantation in Asia: Problems and practice. J Gastroenterol Hepatol 1998;13:S308-10. [PMID: 28976673 DOI: 10.1111/j.1440-1746.1998.tb01899.x] [Reference Citation Analysis]
19 Mutimer D. Long term outcome of liver transplantation for viral hepatitis: is there a need to re-evaluate patient selection? Gut 1999;45:475-6. [PMID: 10486345 DOI: 10.1136/gut.45.4.475] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
20 Niederau C. Chronic hepatitis B in 2014: Great therapeutic progress, large diagnostic deficit. World J Gastroenterol 2014; 20(33): 11595-11617 [PMID: 25206267 DOI: 10.3748/wjg.v20.i33.11595] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
21 Crismale JF, Ahmad J. Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. World J Gastroenterol 2019; 25(47): 6799-6812 [PMID: 31885421 DOI: 10.3748/wjg.v25.i47.6799] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
22 Hu TH, Tsai MC, Chen YT, Chien YS, Hung CH, Chen TC, Tseng PL, Chang KC, Yen YH. The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up. Hepatol Int. 2011;16. [PMID: 21744310 DOI: 10.1007/s12072-011-9295-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
23 King RW, Ladner SK, Miller TJ, Zaifert K, Perni RB, Conway SC, Otto MJ. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother 1998;42:3179-86. [PMID: 9835512 DOI: 10.1128/AAC.42.12.3179] [Cited by in Crossref: 106] [Cited by in F6Publishing: 51] [Article Influence: 4.6] [Reference Citation Analysis]
24 Dodson SF. Monotherapy Versus Combination Therapy in the Prevention of Hepatitis B in Liver Transplant Recipients: . BioDrugs 2000;14:205-9. [DOI: 10.2165/00063030-200014040-00001] [Reference Citation Analysis]
25 Walsh K, Alexander GJ. Update on chronic viral hepatitis. Postgrad Med J 2001;77:498-505. [PMID: 11470928 DOI: 10.1136/pmj.77.910.498] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 0.9] [Reference Citation Analysis]
26 McMaster P. More radical surgical excision for hepatocellular cancer? Lancet 1996;348:1601-2. [PMID: 8961985 DOI: 10.1016/S0140-6736(05)65689-9] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
27 Wang P, Tam N, Wang H, Zheng H, Chen P, Wu L, He X. Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis. PLoS One. 2014;9:e104480. [PMID: 25102072 DOI: 10.1371/journal.pone.0104480] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.9] [Reference Citation Analysis]
28 Cangelosi Q, Means SA, Ho H. A multi-scale spatial model of hepatitis-B viral dynamics. PLoS One 2017;12:e0188209. [PMID: 29216213 DOI: 10.1371/journal.pone.0188209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
29 Weakley T, Rajender Reddy K. Hepatitis B. Curr Treat Options Gastroenterol 1999;2:463-72. [PMID: 11097730 DOI: 10.1007/s11938-999-0050-1] [Reference Citation Analysis]
30 N/A. N/A. Shijie Huaren Xiaohua Zazhi 2004; 12(10): 2432-2434 [DOI: 10.11569/wcjd.v12.i10.2432] [Reference Citation Analysis]
31 Manns MP, Neuhaus P, Atkinson GF, Griffin KE, Barnass S, Vollmar J, Yeang Y, Young CL. Famciclovir treatment of hepatitis B infection following liver transplantation: a long-term, multi-centre study: Famciclovir for post-transplant hepatitis B. Transplant Infectious Disease 2001;3:16-23. [DOI: 10.1034/j.1399-3062.2001.003001016.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
32 Takaki A, Yagi T, Yamamoto K. Safe and cost-effective control of post-transplantation recurrence of hepatitis B. Hepatol Res. 2015;45:38-47. [PMID: 24905970 DOI: 10.1111/hepr.12368] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
33 Onoe T, Tahara H, Tanaka Y, Ohdan H. Prophylactic managements of hepatitis B viral infection in liver transplantation. World J Gastroenterol 2016; 22(1): 165-175 [PMID: 26755868 DOI: 10.3748/wjg.v22.i1.165] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
34 Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, Buchan S, Boxall L, O'Donnell K, Shaw J, Hübscher S, Elias E. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000;46:107-13. [PMID: 10601065 DOI: 10.1136/gut.46.1.107] [Cited by in Crossref: 112] [Cited by in F6Publishing: 103] [Article Influence: 5.1] [Reference Citation Analysis]
35 Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int. 2008;2:152-162. [PMID: 19669300 DOI: 10.1007/s12072-008-9056-3] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 5.1] [Reference Citation Analysis]
36 Anselmo DM, Ghobrial RM, Jung LC, Weaver M, Cao C, Saab S, Kunder G, Chen PW, Farmer DG, Yersiz H. New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg. 2002;235:611-619; discussion 619-620. [PMID: 11981206 DOI: 10.1097/00000658-200205000-00002] [Cited by in Crossref: 82] [Cited by in F6Publishing: 73] [Article Influence: 4.1] [Reference Citation Analysis]
37 Sawyer RG, McGory RW, Gaffey MJ, McCullough CC, Shephard BL, Houlgrave CW, Ryan TS, Kuhns M, McNamara A, Caldwell SH. Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg. 1998;227:841-850. [PMID: 9637547 DOI: 10.1097/00000658-199806000-00007] [Cited by in Crossref: 120] [Cited by in F6Publishing: 103] [Article Influence: 5.0] [Reference Citation Analysis]
38 Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs. 1999;58:101-141. [PMID: 10439933 DOI: 10.2165/00003495-199958010-00015] [Cited by in Crossref: 96] [Cited by in F6Publishing: 78] [Article Influence: 4.2] [Reference Citation Analysis]
39 Takaki A, Yagi T, Yasunaka T, Sadamori H, Shinoura S, Umeda Y, Yoshida R, Sato D, Nobuoka D, Utsumi M. Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation? J Gastroenterol. 2013;48:1373-1383. [PMID: 23435670 DOI: 10.1007/s00535-013-0763-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
40 Bain VG. Hepatitis B in transplantation. Transpl Infect Dis 2000;2:153-65. [PMID: 11429028 DOI: 10.1034/j.1399-3062.2000.020402.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
41 Vierling JM. Management of HBV Infection in Liver Transplantation Patients. Int J Med Sci 2005;2:41-9. [PMID: 15968339 DOI: 10.7150/ijms.2.41] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
42 Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 109] [Cited by in F6Publishing: 121] [Article Influence: 10.9] [Reference Citation Analysis]
43 Tchervenkov JI, Tector AJ, Barkun JS, Sherker A, Forbes CD, Elias N, Cantarovich M, Cleland P, Metrakos P, Meakins JL. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Ann Surg 1997;226:356-65; discussion 365-8. [PMID: 9339942 DOI: 10.1097/00000658-199709000-00015] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 1.4] [Reference Citation Analysis]
44 Ferrarese A, Zanetto A, Gambato M, Bortoluzzi I, Nadal E, Germani G, Senzolo M, Burra P, Russo FP. Liver transplantation for viral hepatitis in 2015. World J Gastroenterol 2016; 22(4): 1570-1581 [PMID: 26819523 DOI: 10.3748/wjg.v22.i4.1570] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
45 Zuckerman AJ, Lavanchy D. Treatment options for chronic hepatitis. Antivirals look promising. BMJ. 1999;319:799-800. [PMID: 10496806 DOI: 10.1136/bmj.319.7213.799] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
46 Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009; 15(20): 2489-2499 [PMID: 19468999 DOI: 10.3748/wjg.15.2489] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
47 Yasunaka T, Takaki A, Yagi T, Iwasaki Y, Sadamori H, Koike K, Hirohata S, Tatsukawa M, Kawai D, Shiraha H. Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int. 2011;5:918-926. [PMID: 21484119 DOI: 10.1007/s12072-011-9265-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
48 Montalbano M, Neff GW. Management of recurrent viral hepatitis B and C after liver transplantation. Curr Gastroenterol Rep 2006;8:60-6. [PMID: 16510036 DOI: 10.1007/s11894-006-0065-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
49 Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother. 1997;41:1444-1448. [PMID: 9210663 DOI: 10.1128/aac.41.7.1444] [Cited by in Crossref: 218] [Cited by in F6Publishing: 65] [Article Influence: 8.7] [Reference Citation Analysis]
50 Herrero JI, Quiroga J, Sangro B, Sola I, Riezu-Boj JI, Pardo F, Prieto J. Effectiveness of lamivudine in treatment of acute recurrent hepatitis B after liver transplantation. Dig Dis Sci 1998;43:1186-9. [PMID: 9635605 DOI: 10.1023/a:1018887203545] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
51 Lenci I, Milana M, Grassi G, Manzia TM, Gazia C, Tisone G, Angelico R, Baiocchi L. Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger? World J Gastroenterol 2020; 26(18): 2166-2176 [PMID: 32476783 DOI: 10.3748/wjg.v26.i18.2166] [Cited by in CrossRef: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Ghaziani T, Sendi H, Shahraz S, Zamor P, Bonkovsky HL. Hepatitis B and liver transplantation: Molecular and clinical features that influence recurrence and outcome. World J Gastroenterol 2014; 20(39): 14142-14155 [PMID: 25339803 DOI: 10.3748/wjg.v20.i39.14142] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
53 Kewn S, Hoggard PG, Sales SD, Johnson MA, Back DJ. The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells. Br J Clin Pharmacol 2000;50:597-604. [PMID: 11136299 DOI: 10.1046/j.1365-2125.2000.00302.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]